	US 12,076,324 B2
	Cancer treatments using combinations of CDK and ERK inhibitors
Saurabh Saha, Wellesley Hills, MA (US); Dean Welsch, Parkville, MO (US); Gary DeCrescenzo, Parkville, MO (US); and Jeffrey James Roix, Boston, MA (US)
Assigned to BIOMED VALLEY DISCOVERIES, INC., Kansas City, MO (US)
Filed by BIOMED VALLEY DISCOVERIES, INC., Kansas City, MO (US)
Filed on May 1, 2023, as Appl. No. 18/310,034.
Application 16/856,849 is a division of application No. 15/105,924, granted, now 11,013,743, issued on May 25, 2021, previously published as PCT/US2014/071747, filed on Dec. 19, 2014.
Application 18/310,034 is a continuation of application No. 17/460,743, filed on Aug. 30, 2021, granted, now 11,679,112.
Application 17/460,743 is a continuation of application No. 16/856,849, filed on Apr. 23, 2020, granted, now 11,135,225, issued on Oct. 5, 2021.
Claims priority of provisional application 61/919,597, filed on Dec. 20, 2013.
Prior Publication US 2024/0033267 A1, Feb. 1, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4439 (2006.01); A61K 31/44 (2006.01); A61K 31/496 (2006.01); A61K 31/505 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07D 401/04 (2006.01)

CPC A61K 31/519 (2013.01) [A61K 31/4439 (2013.01); A61K 31/506 (2013.01); A61K 45/06 (2013.01); C07D 401/04 (2013.01)]

24 Claims

1. A method of treating or ameliorating the effects of melanoma in a subject having a somatic NRAS mutation, comprising administering to the subject an effective amount of (i) a first anti-cancer agent, which is BVD-523 or a pharmaceutically acceptable salt thereof and (ii) a second anti-cancer agent, which is LEE-011 or a pharmaceutically acceptable salt thereof, wherein administration of the first and second anti-cancer agents provides a synergistic effect compared to administration of either anti-cancer agent alone.